166 related articles for article (PubMed ID: 23437867)
1. Extended-release niacin/laropiprant for lipid management: observational study in clinical practice.
Steinhagen-Thiessen E; Dänschel W; Buffleben C; Smolka W; Pittrow D; Hildemann SK
Int J Clin Pract; 2013 Jun; 67(6):527-35. PubMed ID: 23437867
[TBL] [Abstract][Full Text] [Related]
2. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
4. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
5. Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
Dänschel W; Steinhagen-Thiessen E; Buffleben C; Pittrow D; Hildemann SK
Curr Med Res Opin; 2013 Jan; 29(1):33-40. PubMed ID: 23157464
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
[TBL] [Abstract][Full Text] [Related]
7. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
[TBL] [Abstract][Full Text] [Related]
8. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Chen F; Maccubbin D; Yan L; Sirah W; Chen E; Sisk CM; Davidson M; Blomqvist P; McKenney JM
Int J Cardiol; 2013 Jul; 167(1):225-31. PubMed ID: 22305632
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
[TBL] [Abstract][Full Text] [Related]
11. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
13. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
Ballantyne C; Gleim G; Liu N; Sisk CM; Johnson-Levonas AO; Mitchel Y
J Clin Lipidol; 2012; 6(3):235-43. PubMed ID: 22658147
[TBL] [Abstract][Full Text] [Related]
14. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
[TBL] [Abstract][Full Text] [Related]
15. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
16. Effects of extended-release niacin with laropiprant in high-risk patients.
; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
[TBL] [Abstract][Full Text] [Related]
17. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
19. Extended-release niacin (nicotinic acid)/laropiprant.
Perry CM
Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
[TBL] [Abstract][Full Text] [Related]
20. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]